We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Cancer Stem Cell Test Improves Survival of Patients with Deadly Brain Tumor

By LabMedica International staff writers
Posted on 09 May 2023

A new study has found that a cancer stem cell test can accurately determine more effective treatments, resulting in increased survival rates for patients with glioblastoma, a lethal brain tumor. More...

Researchers at The University of Cincinnati (Cincinnati, OH, USA) conducted a multi-institutional phase 3 clinical trial focusing on patients whose glioblastoma had recurred after initial treatment. They tested the efficacy of ChemoID, a CLIA and CAP-accredited diagnostic test developed by Cordgenics LLC (Huntington, WV, USA). Patients in the trial were randomized to either have their chemotherapy treatment chosen through ChemoID or have physicians select the chemotherapy using conventional methods. Patients whose treatments were determined using ChemoID experienced a significantly lower risk of death and survived, on average, 3.5 months longer than those in the physician-choice group.

As ChemoID concentrates on selecting treatments utilizing commercially available chemotherapies, this approach provides patients with more effective treatment at a reduced cost. The research team plans to seek funding to further develop ChemoID, potentially modifying the platform to include immunotherapy treatments or targeted therapies. Incorporating anti-cancer therapy that targets cancer stem cells earlier in the treatment plan could eliminate ineffective treatments, allowing patients to receive the maximum therapeutic benefit.

“ChemoID looks at cancer stem cells and their sensitivity to specified drugs to see which ones will work in a given cancer setting,” said Soma Sengupta, MD, PhD, a co-first author of the research and a University of Cincinnati Cancer Center physician-researcher. “We were pleasantly surprised that the ChemoID group did better and that a cancer stem cell-derived test is important in this disease. Where survival in recurrent glioblastoma is extremely poor, 3.5 months or more is wonderful. Some of my patients on this trial are still alive.”

 


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Serological Pipet Controller
PIPETBOY GENIUS
New
Varicella Zoster Virus Assay
LIAISON VZV Assay Panel (IgG HT, IgM)
New
Francisella Tularensis Test
TULAREMIA VIRCLIA IgG+IgM MONOTEST
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Ear wax could be a possible screening medium for Parkinson’s disease (Photo courtesy of 123RF)

Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules

Current tests for Parkinson’s disease (PD) rely heavily on clinical scales and neuroimaging, which are often subjective, expensive, and ill-suited for routine screening. Since most treatments only slow... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: NGS can detect one tumor cell among a million healthy cells from a simple blood sample (Photo courtesy of Shutterstock)

New Tool Detects Breast Cancer Relapses Five Years in Advance

Relapse detection in patients with solid tumors—particularly hormone receptor-positive (HR+) breast cancer—remains a major clinical challenge, as many patients initially respond well to treatment but later... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.